TY - JOUR
T1 - Acute myeloblastic leukemia secondary to myelodysplasia (MDS-AML)
T2 - A comparison of remission induction with three drugs versus standard two-drugs induction
AU - Latagliata, Roberto
AU - Breccia, M.
AU - Pulsoni, A.
AU - Aloe Spiriti, M. A.
AU - D'Elia, G. M.
AU - Spadea, A.
AU - Montefusco, E.
AU - Luzi, G.
AU - Betrò, P.
AU - Petti, M. C.
PY - 2000
Y1 - 2000
N2 - To evaluate the addition of a third drug to standard induction chemotherapy in patients with MDS-AML, 23 patients (males/females 13/10, median age 54.3 years, range 24-74 years, median MDS duration 9.8 months, range 2-39 months) who received a standard 2-drugs induction were compared with 23 patients (males/females 11/12, median age 45.6 months, range 21-60 years, median MDS duration 8.3 months, range 2-29 months) who received an intensified 3-drugs induction with etoposide. CR rate, median CR duration and median OS were similar in both groups (48% vs 56%, 4.8 vs 5.9 months, 6.5 vs 7.0 months respectively). Among responding patients, all but one, who underwent allogeneic bone marrow transplantation, relapsed. In conclusion, addition of a third drug (etoposide) does not seem to significantly improve the poor prognosis of MDS-AML patients.
AB - To evaluate the addition of a third drug to standard induction chemotherapy in patients with MDS-AML, 23 patients (males/females 13/10, median age 54.3 years, range 24-74 years, median MDS duration 9.8 months, range 2-39 months) who received a standard 2-drugs induction were compared with 23 patients (males/females 11/12, median age 45.6 months, range 21-60 years, median MDS duration 8.3 months, range 2-29 months) who received an intensified 3-drugs induction with etoposide. CR rate, median CR duration and median OS were similar in both groups (48% vs 56%, 4.8 vs 5.9 months, 6.5 vs 7.0 months respectively). Among responding patients, all but one, who underwent allogeneic bone marrow transplantation, relapsed. In conclusion, addition of a third drug (etoposide) does not seem to significantly improve the poor prognosis of MDS-AML patients.
KW - Acute myeloblastic leukemia
KW - Cytosine arabinoside
KW - Etoposide
KW - MDS-AML
KW - Myelodysplastic syndromes
KW - Remission induction
UR - http://www.scopus.com/inward/record.url?scp=0033953169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033953169&partnerID=8YFLogxK
M3 - Article
C2 - 10784399
AN - SCOPUS:0033953169
SN - 1042-8194
VL - 36
SP - 539
EP - 541
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5-6
ER -